NJ News (4/22, Dearing) reports on epigenetics research efforts going on in New Jersey to help develop new medications for the treatment of Alzheimer’s. For example, “Princeton Medical Institute is the first study site in the United States to join a clinical trial for ORY-2001, a drug designed to slow cognitive decline and restore memory in patients with mild to moderate Alzheimer’s disease.” Should the experimental medicine be effective, “patients taking part in the study will have already received the drug rather than having to wait years for it to gain FDA approval and become available to the public. (SOURCE: APA Headlines)